Homology Medicines’ Gene Therapy, Gene Editing Programs Advance

Homology Medicines’ Gene Therapy, Gene Editing Programs Advance

282801

Homology Medicines’ Gene Therapy, Gene Editing Programs Advance

Homology Medicines has announced the next steps for its gene therapy and gene editing clinical programs for the treatment of phenylketonuria (PKU). “We ended 2020 with positive data from the dose-escalation phase of the world’s first PKU gene therapy clinical trial, pheNIX, and validation of both our PKU gene therapy and gene editing programs with an equity investment from Pfizer, a leader in genetic medicines,” Arthur Tzianabos, PhD, Homology’s president and CEO, said in a press release.…

You must be logged in to read/download the full post.